Literature DB >> 20352464

Gemcitabine and cisplatin chemotherapy induced reversible posterior leukoencephalopathy syndrome in a bladder cancer patient.

Takahiro Maeda1, Eiji Kikuchi, Kazuhiro Matsumoto, Satoshi Yazawa, Jun Hagiuda, Akira Miyajima, Ken Nakagawa, Hirokazu Fujiwara, Haruhiko Hoshino, Mototsugu Oya.   

Abstract

Reversible posterior leukoencephalopathy syndrome (RPLS) is a rare clinical entity, the common clinical symptoms of which are headache, disturbance of consciousness, altered mental status, seizures, and visual disturbance. Recently, some cases have been reported in association with the increased use of cytotoxic and immunosuppressive agents in cancer patients, and relevant reports have increased with advances in radiological examinations. We describe here the case of a 50-year-old man with advanced bladder cancer who suddenly experienced diminished spontaneity and speech, and finally became semicomatose. Two months previously, he had received gemcitabine and cisplatin chemotherapy. Computed tomography and magnetic resonance imaging revealed symmetrical edema of the posterior occipital lobe and thalamus. Based on these findings, we made a diagnosis of RPLS and treated him with supportive measures. His mental status gradually improved in 2 weeks, although slight neurological symptoms persisted. When the level of consciousness of a cancer patient worsens rapidly, this syndrome should be included in the differential diagnosis and recognized at an early stage. Early supportive management and discontinuation of the causative medication may reverse the clinical and radiological manifestations of the syndrome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20352464     DOI: 10.1007/s10147-010-0068-3

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  9 in total

1.  Severe neurotoxicity caused by gemcitabine treatment.

Authors:  Finn Ole Larsen; Steen Werner Hansen
Journal:  Acta Oncol       Date:  2004       Impact factor: 4.089

2.  Reversible posterior leukoencephalopathy syndrome associated with oxaliplatin.

Authors:  Daryl M Pinedo; Farheen Shah-Khan; Prabodh C Shah
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

Review 3.  Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features.

Authors:  W S Bartynski
Journal:  AJNR Am J Neuroradiol       Date:  2008-03-20       Impact factor: 3.825

Review 4.  Hypertensive emergencies.

Authors:  C J Vaughan; N Delanty
Journal:  Lancet       Date:  2000-07-29       Impact factor: 79.321

5.  Permeability change and brain tissue damage after intracarotid administration of cisplatin studied by double-tracer autoradiography in rats.

Authors:  S Sugimoto; Y L Yamamoto; S Nagahiro; M Diksic
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 6.  Gemcitabine: vascular toxicity and prothrombotic potential.

Authors:  Constantin A Dasanu
Journal:  Expert Opin Drug Saf       Date:  2008-11       Impact factor: 4.250

7.  A reversible posterior leukoencephalopathy syndrome.

Authors:  J Hinchey; C Chaves; B Appignani; J Breen; L Pao; A Wang; M S Pessin; C Lamy; J L Mas; L R Caplan
Journal:  N Engl J Med       Date:  1996-02-22       Impact factor: 91.245

8.  Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images.

Authors:  Diego J Covarrubias; Patrick H Luetmer; Norbert G Campeau
Journal:  AJNR Am J Neuroradiol       Date:  2002 Jun-Jul       Impact factor: 3.825

9.  Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature.

Authors:  Anita Rajasekhar; Thomas J George
Journal:  Oncologist       Date:  2007-11
  9 in total
  9 in total

1.  Posterior Reversible Encephalopathy Syndrome in Patients With Cancer.

Authors:  Samuel Singer; Christian Grommes; Anne S Reiner; Marc K Rosenblum; Lisa M DeAngelis
Journal:  Oncologist       Date:  2015-06-01

2.  Reversible posterior leukoencephalopathy syndrome following combinatorial cisplatin and pemetrexed therapy for lung cancer in a normotensive patient: A case report and literature review.

Authors:  Changqing Xie; Vovanti T Jones
Journal:  Oncol Lett       Date:  2015-12-24       Impact factor: 2.967

3.  Reversible posterior leukoencephalopathy syndrome associated with concurrent bevacizumab, gemcitabine, and oxaliplatin for cholangiocarcinoma.

Authors:  Yongen Chang; Gilbert Mbeo; Susan J Littman
Journal:  J Gastrointest Cancer       Date:  2012-09

Review 4.  Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome: A Case Report and Review of the Literature.

Authors:  Joan How; Margaret Blattner; Susan Fowler; Andrea Wang-Gillam; Suzanne E Schindler
Journal:  Neurologist       Date:  2016-11       Impact factor: 1.398

Review 5.  Delirium in patients with cancer: assessment, impact, mechanisms and management.

Authors:  Peter G Lawlor; Shirley H Bush
Journal:  Nat Rev Clin Oncol       Date:  2014-09-02       Impact factor: 66.675

6.  Posterior reversible encephalopathy syndrome (PRES) in mesenteric leiomyosarcoma: A case report.

Authors:  Ramy Schoucair; Gregory Nicolas; Rechdi Ahdab; Noha Bejjani; Eddie K Abdalla
Journal:  Int J Surg Case Rep       Date:  2018-05-29

7.  Posterior reversible encephalopathy syndrome associated with the use of chemotherapeutic agents: a rare complication after treatment with vinorelbine.

Authors:  Ines Gil; Filipa Serrazina; Miguel Pinto; Miguel Viana-Baptista
Journal:  BMJ Case Rep       Date:  2020-02-16

8.  A case report of posterior reversible encephalopathy syndrome in a patient receiving gemcitabine and cisplatin.

Authors:  Hannah Cherniawsky; Neesha Merchant; Micheal Sawyer; Maria Ho
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.817

9.  Reversible posterior leukoencephalopathy syndrome induced by apatinib: a case report and literature review.

Authors:  Xutong Li; Jie Chai; Zhi Wang; Lin Lu; Qingye Zhao; Jie Zhou; Fang Ju
Journal:  Onco Targets Ther       Date:  2018-07-30       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.